AG
CHRS icon

Advisor Group’s Coherus Oncology CHRS Stock Holding History

Advisor Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$98K Buy
5,440
+117
+2% +$2.16K ﹤0.01% 2959
2019
Q3 		$108K Buy
+5,323
New +$106K ﹤0.01% 2832

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Advisor Group's CHRS Position: Q4 2019 in Review

Advisor Group increased its Coherus Oncology (CHRS) stake by 2.2% in Q4 2019, buying an estimated $2.16K and bringing the position to 5,440 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Advisor Group first reported a position in CHRS in Q3 2019 and has held it in 2 quarters since. The position peaked at $108K in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Advisor Group held 5,440 shares of Coherus Oncology worth $98K as of Q4 2019.
  • Advisor Group bought 117 Coherus Oncology shares in Q4 2019, an estimated $2.16K.
  • Coherus Oncology made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2959 holding.
  • Advisor Group first reported a position in Coherus Oncology in Q3 2019 and has held it in 2 quarters since.
  • Advisor Group's Coherus Oncology position peaked at $108K in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.